[Progress in the study of Her2-targeted cancer therapeutic antibodies]

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Human epidermal growth factor receptor 2 (Her2) is a key tumor surface antigen and type I receptor tyrosine kinase.
• Her2 overexpression correlates with increased tumorigenesis and metastasis.
• Her2-targeted cancer therapy, particularly using therapeutic antibodies, is a significant area of clinical research.

Purpose of the Study:

• To review recent advances in the mechanisms of action for Her2-targeted antibodies.
• To summarize the latest clinical research on various anti-Her2 antibody therapies.
• To provide an overview of Her2 structure and function in relation to antibody targeting.

Main Methods:

• Literature review of Her2-targeted cancer therapies.
• Analysis of different antibody drug classes: monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and "two in one" antibodies.
• Focus on mechanisms of action and clinical outcomes.

Main Results:

• Her2-targeted antibodies represent a critical therapeutic strategy for Her2-overexpressing cancers.
• Diverse antibody formats are being developed, each with unique mechanisms.
• Ongoing clinical research is evaluating the efficacy and safety of these novel antibody therapies.

Conclusions:

• Therapeutic antibodies targeting Her2 are a rapidly evolving and important class of cancer treatments.
• Understanding Her2 structure and function is crucial for developing effective antibody-based therapies.
• Continued research into novel antibody designs and clinical applications holds promise for improving patient outcomes.